Serious Questions to Consider
Our initial post on Celltrion focused on the fundamental risk of whether the company could meet the market's high expectations for its first...
205 Views
Share Buybacks in Korea - Top 9 Insights
In this report, we highlight 39 companies that have announced share buybacks in the past three months (Dec 2015 - Feb 2016) in Korea. We provide...
262 Views
2016 Major IPOs Pipeline in Korea - Part II
In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...
237 Views
2016 Major IPOs Pipeline in Korea
This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in...
292 Views
The Risks of High Expectations for Biosimilars
Celltrion trades at a premium valuation (35x 2016 estimated earnings) based on high expectations for its biosimilar (copycats of biotech) products....
267 Views